Antibiotic-Loaded Hydrogel Coating for the Prevention of Local Infection after Vertebral Surgery: A Retrospective Cohort Analysis

2021 ◽  
Vol 39 ◽  
Author(s):  
Giovanni Parbonetti ◽  
◽  
Adriana Puglisi ◽  
Bruno Rizzo ◽  
Roberto Granata ◽  
...  

Objectives: To preliminarily assess the effectiveness of a highly viscous antibiotic-loaded hydrogel used as a coating for the prevention of superficial and deep Surgical Site Infections (SSIs) after laminectomy and fusion in instrumented vertebral surgery. Methods: We performed a retrospective cohort analysis on 73 consecutive patients who underwent surgery from June 2018 to December 2019 for degenerative spinal disorders (DSD) or traumatic fractures with segmental instability. Patients received the antibiotic-loaded hydrogel over the implants perioperatively and were observed postoperatively for 12 months. Results: Postoperative evaluations showed no adverse events in the study population. None of the patients reported significant pain or functional limitation after surgery. Post-surgically, computed tomography scans confirmed the correct positioning of instruments. At 12 months follow-up, no infection was recorded in the overall population. Conclusion: This retrospective investigation highlights the importance of adopting measures to prevent SSIs in instrumented vertebral surgery. The intraoperative local use of an antibiotic-loaded hydrogel, complementary to systemic antibiotic therapy, appears to minimize the risk of superficial and deep infection.

2021 ◽  
Vol 11 (1) ◽  
pp. 18-23
Author(s):  
S. Shrestha ◽  
K. Hann ◽  
K. W. Y. Kyaw ◽  
P. Koju ◽  
M. Khogali

SETTING: A referral hospital in Kavre, Nepal.OBJECTIVES: To assess 1) compliance with National Antibiotic Treatment Guidelines (NATG), specifically, whether the administration of surgical antibiotic prophylaxis (SAP) (initial dosing and redosing) was in compliance with NATG for patients who were and were not eligible, and 2) development of surgical site infections (SSIs) among patients who underwent surgery in the Department of General Surgery (July–December 2019).DESIGN: This was a retrospective cohort analysis.RESULTS: The analysis included 846 patients, of which 717 (85%) patients were eligible for SAP and 129 (15%) were ineligible. Of those eligible, 708 (99%) received the initial dose; while 65 (50%) of the ineligible did not receive any dose. Of those who received the initial dose, 164 (23%) were eligible for redosing. Of these, only 23 (14%) received at least one redosing and 141 (86%) did not receive it. Overall compliance with NATG was achieved in 75% (632/846) of patients. SSIs occurred in 23 (3%) patients, 8 (35%) of whom did not have SAP administered according to NATG.CONCLUSION: A relatively high overall compliance with NATG for SAP administration was reported. Recommendations were made to improve compliance among those who were ineligible for SAP and those who were eligible for redosing.


2020 ◽  
Vol 72 (2) ◽  
Author(s):  
Silvia Alboresi ◽  
Alice Sghedoni ◽  
Giulia Borelli ◽  
Stefania Costi ◽  
Laura Beccani ◽  
...  

Author(s):  
Serena Xodo ◽  
Fabiana Cecchini ◽  
Lisa Celante ◽  
Alice Novak ◽  
Emma Rossetti ◽  
...  

2021 ◽  
Vol 10 (5) ◽  
pp. 1058
Author(s):  
Grégoire Rocher ◽  
Thomas Gaillard ◽  
Catherine Uzan ◽  
Pierre Collinet ◽  
Pierre-Adrien Bolze ◽  
...  

To determine if the time-to-chemotherapy (TTC) after primary macroscopic complete cytoreductive surgery (CRS) influences recurrence-free survival (RFS) and overall survival (OS) in patients with epithelial ovarian cancer (EOC). We conducted an observational multicenter retrospective cohort analysis of women with EOC treated from September 2006 to November 2016 in nine institutions in France (FRANCOGYN research group) with maintained EOC databases. We included women with EOC (all FIGO stages) who underwent primary complete macroscopic CRS prior to platinum-based adjuvant chemotherapy. Two hundred thirty-three patients were included: 73 (31.3%) in the early-stage group (ESG) (FIGO I-II), and 160 (68.7%) in the advanced-stage group (ASG) (FIGO III-IV). Median TTC was 43 days (36–56). The median OS was 77.2 months (65.9–106.6). OS was lower in the ASG when TTC exceeded 8 weeks (70.5 vs. 59.3 months, p = 0.04). No impact on OS was found when TTC was below or above 6 weeks (78.5 and 66.8 months, respectively, p = 0.25). In the whole population, TTC had no impact on RFS or OS. None of the factors studied were associated with an increase in TTC. Chemotherapy should be initiated as soon as possible after CRS. A TTC greater than 8 weeks is associated with poorer OS in patients with advanced stage EOC.


Sign in / Sign up

Export Citation Format

Share Document